First Time Loading...

ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 4.97 USD 6.2%
Updated: Apr 24, 2024

ADC Therapeutics SA
Operating Income

Last Value
3-Years CAGR
5-Years CAGR
Quarterly
Annual
TTM
|

ADC Therapeutics SA
Operating Income Peer Comparison

Comparables:
ACIU
CRSP
BSLN
IDIA
KURN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
ADC Therapeutics SA
NYSE:ADCT
Operating Income
-$166m
CAGR 3-Years
9%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Operating Income
-CHf53.6m
CAGR 3-Years
4%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Operating Income
-$222.5m
CAGR 3-Years
14%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Operating Income
CHf19.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Idorsia Ltd
SIX:IDIA
Operating Income
-CHf803m
CAGR 3-Years
-19%
CAGR 5-Years
-152%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Operating Income
-CHf8.7m
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
N/A

See Also

What is ADC Therapeutics SA's Operating Income?
Operating Income
-166m USD

Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Operating Income amounts to -166m USD.

What is ADC Therapeutics SA's Operating Income growth rate?
Operating Income CAGR 5Y
-6%

Over the last year, the Operating Income growth was -37%. The average annual Operating Income growth rates for ADC Therapeutics SA have been 9% over the past three years , -6% over the past five years .